Drug Trial Radar · NCT06539481
Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye.
Last checked: Nov 20, 2026Latest source record: Aug 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Aug 31, 2024
Primary completion
Jul 15, 2026
Study completion Oct 31, 2028
Sponsor
- Lead sponsor
- Alimera SciencesIndustry
- Sponsor type
- Industry
- First posted
- Aug 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim is to test how safe and effective the medicine ILUVIEN® (190μg) is for children and adolescents, who have non-infectious uveitis that keeps coming back and affects the back of the eye. The main thing Alimera wants to find out is how well the implant works for treating non-infectious uveitis in the back of the eye. Treatment success will be measured after 6 months of using the implant. The treatment will be considered successful if two things happen: 1. No swelling in the back of the eye called cystoid macular oedema; 2. A decrease in the cloudiness inside the eye, called vitreous haze, by at least two levels compared to how it was before the treatment, or the vitreous haze is completely gone. Participants will: 1. Receive a single treatment with ILUVIEN®, which is a tiny tube that is to be implanted in the eye and releases low levels of the corticosteroid (fluocinolone acetonide) in the eye for up to 36 months. 2. Be followed for 36 months for checkups and tests
Conditions
- Non-infectious Uveitis Affecting the Posterior Segment of the Eye
Interventions
fluocinolone acetonide 190 microgramsDrug
ILUVIEN®, is a tiny tube that is to be implanted in the eye and releases low levels of the corticosteroid (fluocinolone acetonide) in the eye. ILUVIEN® delivers corticosteroid directly to the intended site of action for up to 36 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absence of cystoid macular oedema on Optical Coherence Tomography and a decrease from baseline in vitreous haze grade of ≥2 steps, or absence of vitreous haze.Time frame: 6 months after administration
- Rate of cataract formation and Rate of IOP elevationTime frame: 6 months after administration
Locations
6 sites in 3 countries. Site status is shown where the registry gives one.
Charité - Universitätsmedizin Berlin Institute of Health Department of Ophthalmology
Berlin, Germany · Not yet recruiting
Augenzentrum am St. Franziskus-Hospital Münster
Münster, Germany · Recruiting
Hospital Universitario Cruces
Bilbao, Spain · Recruiting
Fundación Jiménez Díaz
Madrid, Spain · Recruiting
University of Bristol Bristol Medical School
Bristol, United Kingdom · Recruiting
Sheffield Teaching Hospitals NHS Foundation Trust and Sheffield Children NHS Foundation Trust
Sheffield, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.